Innovation Pharmaceuticals Inc (IPIX)

[baytdr]

Partnerships are inevitable, this informative and exceptionally positive update indicates to me that IPIX is not pausing but is rather more committed than ever to completing existing trials in order to enlist the aid of a global player with the aid of endoscopic proof of efficacy;

“On the heels of a successful Proof-of-Concept study of Brilacidin in IBD, we look forward to continuing the Company’s momentum in this area,”

“Given IBD’s complex pathogenesis and variability in patient response to any one drug, new treatments are needed. More broadly, discussions remain ongoing with numerous global pharmaceutical companies, which, like us, see the considerable potential of Brilacidin as a multi-faceted drug candidate, with possible application across multiple therapeutic areas. The beauty of Brilacidin is that it was designed not only to mimic but actually to improve the body’s innate immune response—and that’s exactly what we’re now seeing translate into the clinic in the form of favorable patient outcomes.”